JMP Securities initiated coverage of KalVista (KALV) with an Outperform rating and $19 price target KalVista is developing sebetralstat, a small-molecule plasma kallikrein inhibitor, which could be the first oral on-demand therapy for hereditary angioedema and take “substantial” market share from currently approved injectables, the analyst tells investors in a research note. The firm sees approval as likely by the June 17 FDA action date.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.